Deals In Depth: April 2018
Executive Summary
For potentially over $1 billion, Boehringer Ingelheim gained an early-stage anti-cancer immunotherapy from OSE. Novartis again expanded its gene therapy capabilities in the $8.4 billion buy of AveXis. Biopharma and device financing both decreased.